Objectives of Study:
|
Explore the clinical efficacy of Xingnao Jianshen Decoction combined with basic western medicine treatment on patients with clinical acute cerebral infarction (experimental phlegm-heat-fu-organs) According to the clinical collection of patients with ischemic stroke (phlegm-heat-fu organs), they were divided into experimental group and control group with 36 cases each according to the enrollment unit. The patients enrolled in the Sino-Japanese Union Hospital of Jilin University were the control group, and the treatment was given. The treatment drugs recommended by Western medicine in the "Chinese Acute Ischemic Stroke Diagnosis and Treatment Guide 2018", the test group was added with the traditional Chinese medicine compound ---Xingnao Jianshen Recipe on the basis of the control group medication, and the drug intervention was given for 10±1 days of treatment The neurological deficit score scale (National Institutes of Health Neurological Deficiency Score, NIHSS); Barthel Index (BI) Rating Scale; Modified Rankin Scale (mRS); Ischemic Stroke TCM Syndrome Diagnosis Scale The statistics of the data, clarify the clinical treatment effect. To clarify the pharmacodynamic mechanism of Xingnao Jianshen Recipe is another key issue of this project: the application of HPLC/MS-MS technology to detect the components of the compound, the next step is to use transcriptomics to explore specific pharmacodynamic pathways in the MCAO rat model And targets.
|
Exclusion criteria:
|
1.Diagnose patients with other brain diseases based on head CT or MRI, such as cerebral hemorrhage, brain tumor, brain trauma, TIA;
2.Patients in a coma;
3.Patients need or have undergone thrombolysis or endovascular treatment;
4.People with allergies, allergic to test drugs or related ingredients;
5.Patients whose blood pressure is still less than 90/60mmHg or >=220mmHg/120mmHg after treatment;
6.Complicated with severe liver and kidney damage, and whose ALT, AST, Cr, and BUN levels are 1.5 times higher than normal;
7.Accompanied by other complications and complications that affect drug evaluation, such as severe cardiac insufficiency, severe mental illness, depression and dementia after stroke, cerebral hemorrhage after cerebral infarction, etc.;
8.Past ischemic stroke mRS score >= 2 points;
9.Disabled patients (blindness, deafness, dumbness, intellectual disability, mental disability, etc.) stipulated by the law, and physical disability caused by other diseases affect the assessors of neurological impairment;
10.Patients with bleeding tendency or severe bleeding within 3 months;
11.Suspected or true history of alcohol or drug abuse, or other circumstances that reduce the possibility of enrollment or complicate enrollment according to the judgment of the investigator;
12.Menstrual women, pregnant women and lactating women, those who have a positive pregnancy test or have recent birth plans;
13.Participating in other clinical trials or participating in other drug clinical trials within 3 months.
|